Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes

A Drilon, ZI Hu, GGY Lai, DSW Tan - Nature reviews Clinical oncology, 2018 - nature.com
The gene encoding the receptor-tyrosine kinase RET was first discovered more than three
decades ago, and activating RET rearrangements and mutations have since been identified …

RET fusions in solid tumors

AY Li, MG McCusker, A Russo, KA Scilla… - Cancer treatment …, 2019 - Elsevier
The RET proto-oncogene has been well-studied. RET is involved in many different
physiological and developmental functions. When altered, RET mutations influence disease …

RET tyrosine kinase signaling in development and cancer

E Arighi, MG Borrello, H Sariola - Cytokine & growth factor reviews, 2005 - Elsevier
The variety of diseases caused by mutations in RET receptor tyrosine kinase provides a
classic example of phenotypic heterogeneity. Gain-of-function mutations of RET are …

[HTML][HTML] Thyroid carcinoma: molecular pathways and therapeutic targets

YE Nikiforov - Modern Pathology, 2008 - Elsevier
Thyroid cancer is the most common malignant tumor of the endocrine system. The most
frequent type of thyroid malignancy is papillary carcinoma. These tumors frequently have …

BAY 43-9006 inhibition of oncogenic RET mutants

F Carlomagno, S Anaganti, T Guida… - Journal of the …, 2006 - academic.oup.com
Background: Medullary and papillary thyroid carcinomas are often associated with
oncogenic activation of the RET tyrosine kinase. We evaluated whether the biaryl urea BAY …

RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors

JWB de Groot, TP Links, JTM Plukker… - Endocrine …, 2006 - academic.oup.com
The RET gene encodes a receptor tyrosine kinase that is expressed in neural crest-derived
cell lineages. The RET receptor plays a crucial role in regulating cell proliferation, migration …

Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray …

TJ Giordano, R Kuick, DG Thomas, DE Misek, M Vinco… - Oncogene, 2005 - nature.com
Thyroid cancer poses a significant clinical challenge, and our understanding of its
pathogenesis is incomplete. To gain insight into the pathogenesis of papillary thyroid …

RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis

R Ciampi, YE Nikiforov - Endocrinology, 2007 - academic.oup.com
Thyroid papillary carcinoma is the most common type of endocrine cancer. It is frequently
associated with genetic alterations leading to activation of the MAPK signaling pathway. The …

Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors

F Carlomagno, T Guida, S Anaganti, G Vecchio… - Oncogene, 2004 - nature.com
We have recently demonstrated that the pyrazolopyrimidines PP1 and PP2 and the 4-
anilinoquinazoline ZD6474 display a strong inhibitory activity (IC 50⩽ 100 n M) towards …

An update on molecular biology of thyroid cancers

O Omur, Y Baran - Critical reviews in oncology/hematology, 2014 - Elsevier
Differentiated thyroid cancer (DTC) is the most common endocrinological malignancy. There
are several histological variants such as papillary and follicular thyroid carcinoma. Many …